FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations
Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.
donanemab
An experimental Alzheimer's drug outperforms one just approved by the FDA
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.